A detailed history of Northern Trust Corp transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 76,960 shares of TCRX stock, worth $440,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,960
Previous 71,611 7.47%
Holding current value
$440,980
Previous $417,000 46.52%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$4.89 - $8.3 $26,156 - $44,396
5,349 Added 7.47%
76,960 $611,000
Q4 2023

Feb 13, 2024

SELL
$2.66 - $6.76 $970 - $2,467
-365 Reduced 0.51%
71,611 $417,000
Q3 2023

Nov 13, 2023

BUY
$2.04 - $2.94 $116,118 - $167,347
56,921 Added 378.09%
71,976 $184,000
Q2 2023

Aug 11, 2023

BUY
$1.64 - $4.85 $1,484 - $4,389
905 Added 6.4%
15,055 $37,000
Q1 2023

May 15, 2023

BUY
$1.66 - $3.32 $4,822 - $9,644
2,905 Added 25.83%
14,150 $29,000
Q4 2022

Feb 13, 2023

BUY
$1.49 - $2.86 $16,755 - $32,160
11,245 New
11,245 $17,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $108M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.